Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices

Details for Australian Patent Application No. 2004290862 (hide)

International Classifications

Event Publications

1 June 2006 PCT application entered the National Phase

PCT publication WO2005/049061 Priority application(s): WO2005/049061

3 June 2010 Application Accepted

Published as AU-B-2004290862

30 September 2010 Standard Patent Sealed

17 March 2011 Extension of Term of Standard Patents

Novo Nordisk A/S The earliest first regulatory approval date provided by the patentee 26 Aug 2010 For the goods VICTOZA liraglutide (rys) Applications Accepted The following application(s) for Extension of Term have been accepted under Section 74. Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be filed at the Patent Office within the prescribed time.

24 March 2011 Extension of Term of Standard Patents

Novo Nordisk A/S The earliest first regulatory approval date provided by the patentee 26 Aug 2010 For the goods VICTOZA liraglutide (rys) Address for service in Australia: Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

25 August 2011 Extension granted

Novo Nordisk A/S The earliest first regulatory approval date provided by the patentee 26 Aug 2010 For the goods VICTOZA liraglutide (rys) Extensions of Term of Standard Patents Extension of Term of a Standard Patent relating to Pharmaceutical Substances Extensions granted Extension of Term of patent pursuant to Section 77 expires on 26 Aug 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.